Open access
Aug 2026
Association between empagliflozin exposure and skeletal muscle degeneration in patients with heart failure
Sodium–glucose co-transporter 2 inhibitors (SGLT2i) have become essential in the management of heart failure. Their prognostic benefits are consistent across older adults, frail, and underweight patients, but there may be potential adverse effects on the skeletal muscle. In this prospective single-centre observational...
Tatsuya Nishikawa, Nobuto Nakanishi, Kayo Osawa et al.
· BMC Cardiovascular Disorders · 0 citations